Safety and Effectiveness Study of PM8002, a Bispecific Antibody Targeting PD-L1 and VEGF-A, in Adults With Advanced Solid Tumors

What this Trial Is About

Researchers are evaluating PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, in adults with advanced solid tumors. The study aims to understand the safety, tolerability, how the drug is processed in the body, immune response, and its anti-tumor activity. This trial is conducted in phases Ib and IIa to assess these factors in patients with malignant neoplasms. Participants will receive PM8002 as an intravenous infusion every 2 or 3 weeks. The treatment is given as a single agent without combination therapies. The study monitors participants for dose-limiting toxicities during the first three weeks and records treatment-related side effects for up to 30 days after the last dose. The trial also evaluates tumor response and disease control for up to approximately two years. Throughout the study, participants undergo regular assessments to measure tumor size, survival rates, and immune responses. These evaluations include tracking objective response rates, duration of response, progression-free survival, and overall survival. Safety monitoring includes checking for adverse events and anti-drug antibodies. The total participation time may extend to about two years, including follow-up periods after treatment ends.

PM8002 in the Treatment of Patients With Advanced Solid Tumors